MRI free water as a biomarker for cognitive performance: Validation in the MarkVCID consortium

Pauline Maillard PhD1 | Laura J. Hillmer2 | Hanzhang Lu PhD3 | Konstantinos Arfanakis PhD4,5 | Brian T. Gold PhD6 | Christopher E. Bauer PhD6 | Joel H. Kramer PsyD7 | Adam M. Staffaroni PhD7 | Lara Stables PhD7 | Danny J.J. Wang PhD8 | Sudha Seshadri MD9,10 | Claudia L. Satizabal PhD9,10,11 | Alexa Beiser PhD9,12 | Mohamad Habes PhD10 | Myriam Fornage MD13,14 | Thomas H. Mosley PhD15 | Gary A. Rosenberg MD2 | Baljeet Singh BS1 | Herpreet Singh MA16 | Kristin Schwab BA16 | Karl G. Helmer PhD17,18 | Steven M. Greenberg MDPhD16 | Charles DeCarli MD1 | Arvind Caprihan PhD19

1Department of Neurology, University of California, Davis, California, USA
2Department of Neurology, University of New Mexico, Albuquerque, New Mexico, USA
3Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
4Department of Biomedical Engineering, Illinois Institute of Technology, Chicago, Illinois, USA
5Rush Alzheimer’s Disease Center, Department of Diagnostic Radiology and Nuclear Medicine, Rush University Medical Center, Chicago, Illinois, USA
6Department of Neuroscience, University of Kentucky, Lexington, Kentucky, USA
7Department of Neurology, Memory and Aging Center, Weill Institute for Neurosciences, University of California, San Francisco, California, USA
8Laboratory of FMRI Technology (LOFT), Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
9Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, USA
10Glenn Biggs Institute for Alzheimer’s & Neurodegenerative Diseases, University of Texas Health San Antonio, San Antonio, Texas, USA
11Department of Population Health Sciences, University of Texas Health San Antonio, San Antonio, Texas, USA
12Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA
13Brown Foundation Institute of Molecular Medicine, McGovern Medical School, School of Public Health, The University of Texas Health Science Center at Houston, Houston, Texas, USA
14Human Genetics Center, School of Public Health, The University of Texas Health Science Center at Houston, Houston, Texas, USA
15MIND Center, University of Mississippi Medical Center, Jackson, Mississippi, USA
16Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA
17Department of Radiology, Harvard Medical School, Boston, Massachusetts, USA
18Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA
19The Mind Research Network, Albuquerque, New Mexico, Albuquerque, New Mexico, USA
**Introduction:** To evaluate the clinical validity of free water (FW), a diffusion tensor imaging–based biomarker kit proposed by the MarkVCID consortium, by investigating the association between mean FW (mFW) and executive function.

**Methods:** Baseline mFW was related to a baseline composite measure of executive function (EFC), adjusting for relevant covariates, in three MarkVCID sub-cohorts, and replicated in five, large, independent legacy cohorts. In addition, we tested whether baseline mFW predicted accelerated EFC score decline (mean follow-up time: 1.29 years).

**Results:** Higher mFW was found to be associated with lower EFC scores in MarkVCID legacy and sub-cohorts ($p$-values $< 0.05$). In addition, higher baseline mFW was associated significantly with accelerated decline in EFC scores ($p = 0.0026$).

**Discussion:** mFW is a sensitive biomarker of cognitive decline, providing a strong clinical rational for its use as a marker of white matter (WM) injury in multi-site observational studies and clinical trials of vascular cognitive impairment and dementia (VCID).

**KEYWORDS** biomarker, diffusion tensor imaging, free water, small vessel disease, vascular contributions to cognitive impairment and dementia, VCID, white matter injury

**1 | BACKGROUND**

In recent efforts to improve early identification, staging, and prediction of risk of persons at risk for vascular contributions to vascular cognitive impairment and dementia (VCID) in relation with small vessel disease, the US National Institutes of Health (NIH) National Institute of Neurological Disorders and Stroke (NINDS) funded the MarkVCID consortium to identify and validate fluid- and imaging-based biomarkers for the small vessel diseases associated with VCID. Free water (FW) measured from a diffusion magnetic resonance imaging (MRI) is one of the 11 biomarkers selected for validation for VCID. Free water (FW) measured from a diffusion magnetic resonance imaging (MRI) is one of the 11 biomarkers selected for validation for VCID. The FW measure is derived from diffusion tensor imaging (DTI) and reflects the amount of water molecules that are relatively unrestricted by their local microenvironment in the white matter (WM) tissue. FW has received recent attention as a sensitive measure of cerebral injury in association with cognition. In addition, FW has been found to be associated with a network of inflammatory biomarkers in older individuals, with vascular risk factors (VRFs) in relatively healthy adults (including systolic blood pressure and arterial stiffness), and with white matter hyperintensities (WMHs), supporting the role of FW as a marker of vascular disease.

The biomarker validation consisted of two parts following recommendations proposed by the US Food and Drug Administration (FDA-NIH) Biomarker Working Group: (1) instrument validation and (2) clinical validation. The instrument validation consisted of demonstrating that the measurement was reproducible with respect to: (1) test-retest measurements, (2) measurements across different scanner types, and (3) data processing done by different users. The FW kit instrumental validation phase was recently completed and revealed that the mean FW (mFW) biomarker kit demonstrated very high inter-rater reliability (intraclass correlation coefficient [ICC] = 0.997), test-retest repeatability (ICC = 0.995), and inter-scanner reproducibility (ICC = 0.96). Because of the high reproducibility shown in the instrument validation study no further data harmonization is required within the MarkVCID data sets.

The clinical validation hypothesis of the FW kit, pre-specified before the start of the study (https://markvcid.partners.org/consortium-protocols-resources) is that mFW will be cross-sectionally associated with a composite score of executive functions (EFCs) from the MarkVCID cohorts. In order to show that these results are also valid in other cohorts, we replicated the analysis in five independent data sources for which clinical and DTI data were available. Finally, to further provide supporting evidence of the FW kit’s clinical relevance, we explored whether baseline mFW measures predicted future decline in EFC scores using individuals from the MarkVCID cohorts for whom longitudinal data were available.

**2 | METHOD**

**2.1 | Cohorts**

**2.1.1 | MarkVCID cohorts**

MarkVCID is a consortium of seven sites: Johns Hopkins University School of Medicine (JHU); Rush University Medical Center/Illinois Institute of Technology (RUSH); Universities of California San Francisco, Davis, and Los Angeles (UCSF/UCD/UCLA); University of...
Kentucky (UKY); University of New Mexico Health Sciences Center (UNM); University of Southern California (USC), and the University of Texas Health Science Center at San Antonio (UTHSCSA, operating as part of the Cohorts for Heart and Aging Research in Genomic Epidemiology [CHARGE] consortium site); and a central coordinating center (Massachusetts General Hospital) working with the NINDS and National Institute on Aging (NIA) under cooperative agreements. Six MarkVCID sites that participated in the clinical validation of the FW kit included UNM, UCSF, UKY, USC, JHU, and UTHSCSA. The data used in this study excluded participants with unstable major medical illness, major primary psychiatric disorder, prevalent stroke at the MRI assessment, or other neurological disorders that might confound the assessment of brain volumes, resulting in a total sample of 523 participants. Recruitment sources and inclusion and exclusion criteria for each site cohort are summarized in Table S1. A detailed description of the MarkVCID approach for participant enrollment, clinical and cognitive testing, and sample collection can be found elsewhere. Among these individuals, 180 underwent a second cognitive exam ∼1 year (mean ± SD: 1.29 ± 0.39 years) after their initial exam. Table 1 summarizes subjects’ demographic and clinical characteristics by site for the MarkVCID cohorts used in this study.

2.1.2 Legacy cohorts

Five independent data sources (legacy cohorts) from MarkVCID collaborators were used for replication: Data from UCSF and RUSH, previously acquired data from UCD Alzheimer Disease Research Center, Framingham Heart Study (FHS), including Offspring and Third Generation (Gen3) cohorts, and Atherosclerosis Risk in Communities (ARIC) study from the CHARGE consortium. Briefly, the UCSF cohort includes community-dwelling older adults with normal cognition or mild cognitive impairment (MCI) recruited from the University of California, San Francisco Memory and Aging Center during the 2-year discovery phase of the MarkVCID consortium. RUSH data includes data from the Rush Alzheimer Disease Center collected for the MarkVCID project on 302 Rush Memory and Aging Project (MAP), Religious Orders Study (ROS), Minority Aging Research Study (MARS), Clinical Core, Latino Core non-demented participants. The UCD ADRC cohort includes 173 individuals recruited at the University of California Davis Alzheimer Disease Research Center with ∼74% of the participants recruited through community-based recruitment protocols designed to enhance racial and ethnic diversity and the spectrum of cognitive dysfunction with an emphasis on normal cognition and MCI. FHS is a three-generation, single-site, community-based, ongoing cohort study initiated in 1948 to investigate the risk factors for cardiovascular disease. The present study includes individuals from the Offspring and Gen3 cohort. The ARIC study is a population-based cohort study of atherosclerosis and clinical atherosclerotic diseases. Participants were between age 45 and 64 years at their baseline examination in 1987–1989. Between 2011 and 2013, ARIC conducted a fifth examination, during which MRI scan was also conducted. Table 2 summarizes subjects’ demographic and clinical characteristics for each of the five legacy cohorts.

Institutional review boards approved all participating studies, and study participants provided written informed consent.

2.2 MRI acquisition protocol

2.2.1 MarkVCID protocol

Protocols for MarkVCID DTI sequence have been described previously. Briefly, to balance accuracy and scan time, the MarkVCID DTI protocol uses a single-shell (b = 1000 s/mm²), 40-direction diffusion sequence with a voxel size of 2.0 × 2.0 × 2.0 mm³ and six b = 0 s/mm². A separate scan using a reverse-polarity phase encoding gradient was acquired and used to estimate and correct image distortions in the DTI data.

2.2.2 Legacy cohorts

MRI scans were performed in each study separately following a standard site-specific procedure. Briefly, magnetic field strength of the scanners used in the different studies ranged from 1.5 to 3.0 Tesla. All cohorts used a single-shell DTI acquisition, with non-b-zero values equal to 1000 s/mm². Studies used a 2 × 2 × 2 mm³ resolution (UCSF, UCD ADRC, and RUSH), except FHS and ARIC (2.7 × 2.7 × 3 and 1.8 × 1.8 × 5 mm³, respectively).

DTI acquisition parameters characteristics for the different cohorts are reported in Table S2.

RESEARCH IN CONTEXT

1. Systematic review: This article describes the clinical validation of free water (FW) content, one of the imaging-based biomarkers selected by the MarkVCID consortium. To assess the clinical relevance of the biomarker, the group reviewed existing publicly available methodological papers. References to these sources are appropriately cited.

2. Interpretation: Our results indicate that baseline FW is a sensitive biomarker of cognitive decline, providing a strong clinical rational for its use as a marker of white matter (WM) injury in multi-site observational studies and clinical trials of vascular cognitive impairment and dementia (VCID).

3. Future directions: The next step consists of evaluating the longitudinal association between change in FW and change in cognitive performance.
### TABLE 1  
Participants’ characteristics for all MarkVCID participants and each sub-cohort

| Cohort  | N    | Age        | Sex (F) | Education | Hypertension (Y) | Diabetes (Y) | Smoking Status (Y) | mFW       | EFC       | WMH        | TCV        |
|---------|------|------------|---------|-----------|------------------|--------------|--------------------|------------|-----------|-------------|------------|
| All     | 523  | 71.6 ± 8.1 | 321:61.4| 15.4 ± 3.1 | 265; 50.7        | 103; 19.7    | 195; 37.3          | 0.23 ± 0.05 | -0.51 ± 0.89 | 7.45 ± 11.32 | 1349.0 ± 152.8 |
|         |      | [32.2; 90] |         | [4; 24]   | [4; 24]          | [10; 22]     | [195; 37.3]        | [0.13; 0.47]| [-2.9; 1.75] | [0; 87.17]  | [997.2; 1876.6] |
| JHU     | 86   | 69.3 ± 6.9 | 55; 64  | 16.2 ± 2.5 | 43; 50           | 21; 24.4     | 35; 40.7           | 0.23 ± 0.04 | -0.18 ± 0.79 | 9.6 ± 13.55   | 13125 ± 129.5 |
|         |      | [53.2; 88.9] |   | [12; 24]  | [4; 24]          | [10; 22]     | [35; 40.7]         | [0.16; 0.32]| [-2.2; 1.63] | [0.07; 70.91]| [1022.6; 1642.8] |
| UCSF    | 54   | 77.4 ± 7.4 | 28; 51.9| 17.0 ± 2.1 | 26; 48.1         | 6; 11.1      | 21; 38.9           | 0.25 ± 0.04 | -0.19 ± 0.86 | 9.16 ± 12.16  | 1407.9 ± 168.8 |
|         |      | [55.1; 90] |         | [12; 20]  | [7; 12]          | [2; 12]      | [21; 38.9]         | [0.17; 0.37]| [-2.52; 1.23]| [0.13; 59.57]| [1134.1; 1785.7] |
| UKY     | 125  | 74.2 ± 7.7 | 75; 60  | 16.1 ± 2.6 | 71; 56.8         | 22; 17.6     | 47; 37.6           | 0.24 ± 0.04 | -0.41 ± 0.86 | 7.06 ± 8.69   | 1386.6 ± 140.4 |
|         |      | [55.8; 90] |         | [12; 22]  | [12; 16]         | [12; 22]     | [47; 37.6]         | [0.17; 0.35]| [-2.9; 1.38] | [0.57; 98.8] | [1068.4; 1794.4] |
| UNM     | 79   | 70.8 ± 8.8 | 38; 48.1| 16.4 ± 2.7 | 31; 39.2         | 4; 5.1       | 35; 44.3           | 0.26 ± 0.06 | -0.54 ± 1.01 | 13.2 ± 17.4   | 1416.2 ± 155.4 |
|         |      | [47.5; 90] |         | [10; 20]  | [10; 20]         | [10; 20]     | [35; 44.3]         | [0.18; 0.47]| [-2.86; 1.75]| [0; 87.17]   | [1028.3; 1876.6] |
| USC     | 58   | 68.7 ± 9.0 | 38; 65.5| 11.0 ± 3.3 | 35; 60.3         | 22; 37.9     | 24; 41.4           | 0.21 ± 0.03 | -1.09 ± 0.78 | 4.23 ± 5.08   | 1267.7 ± 142.7 |
|         |      | [32.2; 90] |         | [4; 17]   | [4; 17]          | [4; 17]      | [24; 41.4]         | [0.16; 0.37]| [-2.35; 0.72]| [0.19; 24.45]| [997.2; 1629.8] |
| UTHSCSA | 121  | 69.9 ± 6.9 | 87; 71.9| 14.5 ± 2.7 | 59; 48.8         | 28; 23.1     | 33; 27.3           | 0.19 ± 0.03 | -0.68 ± 0.76 | 3.26 ± 5.04   | 13044 ± 138.4 |
|         |      | [55.9; 89.3] |       | [6; 20]   | [6; 20]          | [6; 20]      | [33; 27.3]         | [0.13; 0.27]| [-2.36; 1.34]| [0.18; 42.91]| [1045.1; 1634.9] |

Note: Continuous variable: mean ± SD [min; max]; categorical variable: N; %. Cohort 1 includes UKY and UCSF, Cohort 2 UNM and JHU, and Cohort 3 UTHSCSA and USC.

Abbreviations: EFC, executive function composite score; mFW, mean free water; TCV, total cranial volume (cc); WMH, white matter hyperintensity (cc). JHU, Johns Hopkins University School of Medicine; RUSH, Rush University Medical Center/Illinois Institute of Technology; UCSF, Universities of California San Francisco, Davis, and Los Angeles; UKY, University of Kentucky; UNM, University of New Mexico Health Sciences Center; USC, University of Southern California; UTHSCSA, University of Texas Health Science Center at San Antonio.
2.3 | Free water kit

Methodology for the FW kit has been described previously. Briefly, the kit requires, as inputs, a four-dimensional (4D) diffusion-weighted (DW) volume (corrected for eddy current distortion), a brain mask, and files containing the b-vector and diffusivity map of each voxel. The model considers two coexisting compartments per voxel: one compartment is a FW compartment, which models isotropic diffusion with a diffusion coefficient of water at body temperature (37°C) fixed to 3 × 10−3 mm²/s, and a second compartment accounts for all other molecules, that is, all intra- and extra-cellular molecules that are hindered or restricted by physical barriers such as axonal membranes and myelin. The kit software generates a measure of mean FW (mFW) within the WM tissue.

WMH and total intracranial volume were also computed using automated procedures as described previously (see Supplemental Method). WMH burden was defined as WMH volume log-transformed and normalized by total intracranial volume.

2.4 | Clinical outcome

Because executive function has been consistently reported to be associated with vascular disease, including FW, the clinical outcome measure used by the FW kit is a composite measure of executive function (EFC) derived using item-response theory (IRT) generated score. Composite scores of executive functions offer advantages such as better reliability, fewer statistical comparisons, and improved power to detect longitudinal change with smaller sample sizes.

The EFC incorporates scores from the following NACC Uniform Data Set (UDS) Version 3 neuropsychological tests: Trail Making Test, Part B (number of correct lines per minute); Number Span Backward (total score); Phonemic fluency (number of correct F-words in 1 min); and Category fluency (number of correct animal responses in 1 min).

2.5 | Biomarker clinical evaluation

The imaging-based biomarker kit clinical validation procedure was pre-defined by the MarkVCID Coordinating Center and requires the kit’s pre-specified primary biological hypothesis (see below) to be tested in at least three MarkVCID cohorts. It also encourages the application of the kit procedure to other independent data sources to provide further evidence of kit validity.

2.5.1 | Primary pre-specified biological hypothesis

The FW kit’s primary pre-specified biological hypothesis is that baseline mFW will be negatively associated with baseline EFC scores with a minimal sample size of 123 individuals (https://markvcid.partners.org/consortium-protocols-resources). To reach this minimum sample size and because the kit previously demonstrated excellent inter-rater reliability, test-retest repeatability, and inter-scanner reproducibility, cross-sectional data from the six MarkVCID participating sites were pooled into three sub-cohorts based solely on recruitment similarity (see Figure 1). Briefly, Euclidian distance was computed between each pair of MarkVCID sites based on average age, education; proportion of female individuals; and proportion of individuals with hypertension, diabetes, and smoking history. At each step, the lowest pairwise distance was used for grouping corresponding sites, resulting in three groups: Cohort 1 (UNM and JHU, N = 169), Cohort 2 (UKY and UCSF, N = 179), and Cohort 3 (UTHSCSA and USC, N = 179). Table S3 summarizes subjects’ demographic and clinical characteristics of each sub-cohort.

### Table 2: Participants’ characteristics for each legacy cohorts

| Cohort | N  | Age (mean ± SD [min; max]) | Sex (F) | Education | Hypertension (Y) | Diabetes (Y) | Smoking Status (Y) | mFW | EFC |
|--------|----|----------------------------|---------|-----------|------------------|---------------|-------------------|-----|-----|
| UCSF   | 182| 70.0 ± 10.8 (45.5; 91)    | 96: 52.7| 17.8 ± 2.8 (5; 26) | 46: 25.3 | 8: 4.4          | 46: 25.3 | 0.23 ± 0.038 (0.11; 0.36) | −1.09 ± 0.74 (−2.94; 0.44) |
| ADRC UCD | 173 | 76.1 ± 6.9 (65; 97)      | 11: 63.6| 14.9 ± 3.9 (0; 20) | 105: 60.7 | 51: 29.5         | Not Available | 0.22 ± 0.05 (0.14; 0.58) | −0.66 ± 0.79 (−2.62; 1.15) |
| RUSH   | 302| 77.5 ± 6.5 (62.1; 97.8)  | 249: 82.5| 16.0 ± 3.7 (5; 30) | 205: 68.1 | 73: 25.3         | 123: 40.7 | 0.24 ± 0.037 (0.15; 0.37) | −0.41 ± 0.72 (−2.43; 1.55) |
| ARIC   | 1837| 76.3 ± 5.3 (67.5; 90)    | 1105: 60.15| 15.3 ± 4.2 (1; 21) | 1370: 75.2 | 600: 33.1        | 97: 5.5  | 0.27 ± 0.062 (0.17; 0.70) | −0.94 ± 0.74 (−2.71; 1.42) |
| FHS    | 2902| 55 ± 14 (25; 92)         | 1569: 54.1| 15.1 ± 3.3 (4; 22) | 932: 32.1 | 212: 7.3         | 213: 7.3 | 0.19 ± 0.034 (0.12; 0.38) | −0.23 ± 0.74 (−2.76; 2.09) |
| Offspring | 889 | 71 ± 8 (48; 92)       | 501: 54.1| 506: 56.9       | 118: 13.3 | 40: 4.5          | 0.23 ± 0.04 (0.15; 0.38) | −0.58 ± 0.73 (−2.63; 1.36) |
| Gen3   | 1937| 48 ± 9 (23; 85)         | 1068: 55.1| 418: 21.6       | 92: 4.8   | 166: 8.6         | 0.18 ± 0.02 (0.12; 0.30) | −0.07 ± 0.69 (−2.76; 2.09) |

Note: Continuous variable: mean ± SD [min; max]; categorical variable: N; %.
Abbreviations: EFC, executive function composite score; mFW, mean free water.
| JHU       | UCSF      | UKY       | UNM       | USC       | UTHSCSA  |
|-----------|-----------|-----------|-----------|-----------|-----------|
| 8.13      | 4.86      | 6.65      | 1.48      | 5.23      | 1.77      |
| 3.36      | 10.60     | 7.52      | 7.90      | 4.55      | 3.75      |

**FIGURE 1** Flowchart describing stepwise sub-cohort grouping. Tables indicate Euclidian distance between each pair of MarkVCID sites based on average age, education, proportion of female, and proportion of individuals with hypertension, diabetes, and smoking history. At each step (top to bottom), the lowest pairwise distance was used for grouping corresponding sites, which were in turn removed from the table.

2.5.2 | Secondary pre-specified biological hypothesis

The FW kit protocol also includes an optional secondary biological hypothesis: higher baseline mFW will predict EFC decline ($\Delta$EFC) over time with a minimal sample size of 175 individuals (https://markvcid.partners.org/consortium-protocols-resources). $\Delta$EFC is defined as the difference between follow-up and baseline EFC score normalized by the time between the two cognitive assessments. To reach the minimum sample size required by the kit, available longitudinal data from all participating MarkVCID sites were pooled together ($N = 180$).

2.5.3 | Testing of primary hypothesis in multiple independent data sources

The FW kit’s primary pre-specified clinical hypothesis was tested on each legacy cohort for replication and generalizability of the findings in the MarkVCID sub-cohort.

2.6 | Statistical analyses

2.6.1 | Primary pre-specified biological hypothesis

To test this hypothesis, a linear regression was used with baseline EFC score as the dependent variable and baseline mFW as the independent variable, adjusting for age, sex, and education (model M1). In a second model, model M1 was additionally adjusted for VRF including presence of diabetes, smoking, and hypertension (model M1 + VRF). This model aimed to estimate the added contribution of mFW above VRF on executive functions.

2.6.2 | Secondary pre-specified biological hypothesis

To evaluate whether baseline mFW correlates with the trajectory of executive functions, we used a linear regression with $\Delta$EFC as the dependent variable and baseline mFW as the independent variable, adjusting for age, sex, education, and baseline EFC score (model M2). In a second analysis, we adjusted model M2 for VRF (Model M2 + VRF).

2.6.3 | Contribution of mFW and WMH burden to EFC scores

To assess the contribution of mFW to explain baseline and longitudinal trajectory of EFC in addition to a classic small vessel disease (SVD) marker such as WMH, we added WMH burden as an independent variable to models M1 + VRF and M2 + VRF. Finally, because mFW is generated within the entire WM mask, including WMH, and to disentangle the contribution of FW and WMH, we replicated these analyses using mFW measures computed within the normal appearing WM voxels only, that is, WM mask excluding WMH voxels.

3 | RESULTS

3.1 | Subjects’ characteristics

As described in the preceding text, enrolled subjects in MarkVCID were pooled into three sub-cohorts to achieve targeted sample sizes. Table S3 summarizes subjects’ demographic and clinical characteristics for the three MarkVCID sub-cohorts. Individuals were 72 ± 8 years of age on average, with older individuals in Cohort 2 (see Table S4). Significant differences appear between Cohort 3 and the two other cohorts: individuals in Cohort 3 were less educated, more likely to have diabetes history, and to be a female, and they had lower mFW, EFC scores, and WMH burden (see Table S4).

Individuals from the legacy cohorts were found to be ≈75 years of age on average, except in the FHS cohort (mean ± SD: 55 ± 14 years old) due to the large number of adult individuals in the Gen3 sub-cohort (mean ± SD: 48 ± 9 years old). Participants were predominantly female (54.1% to 82.5%). The cohorts were found to be very diverse in terms of VRF including the proportion of individuals with hypertension (21.6% to 75.2%), with diabetes (4.4% to 33.1%), and with smoking history (4.5% to 40.7%).

3.2 | Association between baseline EFC scores and baseline mFW in MarkVCID sub-cohorts

In model M1, analyses performed in each MarkVCID sub-cohort revealed that higher baseline mFW was significantly associated with
TABLE 3 Effect of mFW on EFC scores in the different cohorts

| Cohort                         | Model M1 | Model M1 + VRF |
|-------------------------------|----------|----------------|
|                               | Beta     | SE  | p-value | Beta     | SE  | p-value |
| Cross-sectional MarkVCID cohorts |          |     |         |          |     |         |
| Cohort 1                       | −7.417   | 1.279 | <0.001  | −7.325   | 1.315 | <0.001  |
| Cohort 2                       | −8.927   | 1.807 | <0.001  | −8.585   | 1.891 | <0.001  |
| Cohort 3                       | −4.027   | 1.789 | 0.026   | −3.425   | 1.864 | 0.068   |
| Cross-sectional legacy cohorts |          |     |         |          |     |         |
| UCSF                          | −9.87    | 1.76  | <0.0001 | −10.63   | 2.55  | <0.0001 |
| UCD ADRC                      | −6.18    | 0.603 | <0.0001 | −6.16    | 0.605 | <0.0001 |
| RUSH                          | −1.905   | 0.69  | 0.00597 | −2.07    | 0.66  | 0.0018  |
| ARIC                          | −1.24    | 0.304 | <0.0001 | −1.08    | 0.32  | 0.0007  |
| FHS (Offspring and Gen3 combined) | −4.06   | 0.51  | <0.0001 | −3.80    | 0.51  | <0.0001 |
| Offspring                     | −5.17    | 0.74  | <0.0001 | −5.03    | 0.75  | <0.0001 |
| Gen3                          | −1.62    | 0.77  | 0.036   | −1.09    | 0.79  | 0.16    |

Note: Model M1 included baseline EFC as the dependent variable and mFW as the independent variable, adjusting for age, sex, and education. Results for FHS sub-cohorts (Offspring and Gen3) are reported with italic font. RUSH used log10-transformed FW measures to normalize distribution. Abbreviations: EFC, executive function composite score; mFW, mean free water; SE, standard error; VRF, vascular risk factors including diabetes, smoking, and hypertension status. Beta: regression coefficient.

3.3 | Association between EFC scores and mFW in legacy cohorts

The five legacy cohorts all reported significant association between higher baseline mFW and lower baseline EFC score in both models M1 and M1 + VRF (p < 0.001, see Table 3 and Figure 3). In addition, FHS investigators were asked to analyze separately the two sub-cohorts of FHS, that is, Offspring and Gen3. The effect of mFW on EFC score was found significant in both Offspring and Gen3 for model M1 (β = −5.17, p < 0.0001 and β = −1.62, p = 0.036, respectively) indicating that FW is a sensitive biomarker of concomitant cognition even in a younger adult population. When adding VRF as covariates, the association remained in the expected direction but significant in Offspring only (Offspring: β = −5.03, p < 0.0001 and Gen3: β = −1.09, p = 0.16, respectively; see Table 3).

3.4 | Association between changes in EFC scores and baseline mFW in MarkVCID cohorts

Mean (± SD) ΔEFC was found to be −0.032/year (± 0.46). Effect of baseline mFW on ΔEFC was found to be significant in models M2 and M2 + VRF (β = −2.75, p = 0.0026 and β = −2.20, p = 0.0206, respectively), indicating that higher baseline FW is associated with an accelerated decrease in EFC over time (see Figure 4).

3.5 | Contribution of mFW and WMH burden in MarkVCID cohorts

Adding WMH burden to model M1 + VRF did not change the relationships reported in Table 2 between baseline mFW and baseline EFC scores (see Table 4). Of interest, baseline WMH burden was found to be associated with baseline EFC in Cohort 1 (β = −0.159, p = 0.034) but not in Cohorts 2 and 3 (p-values > 0.05, see Table 4). Similarly, including WMH with model M2 + VRF did not change the relationships between baseline mFW and annual change in EFC scores (β = −2.80, p = 0.0096). Baseline WMH burden was not found to be associated with annual change in EFC scores (p = 0.23).

It is important to note that excluding WMH voxels from the WM mask when computing mean FW measures did not change the significance of the associations reported above (see Table S5). These findings suggest that independently of WMH, mFW is a sensitive biomarker of WM integrity in association with baseline EFC and EFC decline over a year.

4 | DISCUSSION

FW is one of the seven imaging-based biomarker kits classified by the MarkVCID consortium as a susceptibility/risk biomarker for the early identification of VCID subjects at risk for cognitive decline, as these participants would be ideal for early intervention. The goal of MarkVCID is to evaluate biomarkers through a formal process with
Benefits of mFW in a clinical trial context

Biological evaluation

Initially introduced to correct conventional metrics derived from single-shell DWI, including fractional anisotropy or mean diffusivity, for extracellular water partial volume contamination, FW has received increasing attention for the past decade as a metric of interest by itself and has been reported consistently as a measure that has received increasing attention for the past decade as a metric of diffusivity, for extracellular water partial volume contamination, FW from single-shell DWI, including fractional anisotropy or mean diffusivity, it would be of interest to investigate whether the effects of PVS and WMH on mFW can be distinguished. The primary biological hypothesis, pre-specified in the FW kit’s protocol, was evaluated and demonstrated in three sub-cohorts of the MarkVCID consortium and successfully replicated in five, large, independent data sources, strongly supporting that mean FW content in the WM tissue, as proposed by the FW kit, is a strong predictor of executive function, as expressed by a composite score based on NACC-derived tests. Although not the primary focus of our study, our results also suggest that higher baseline mFW can predict accelerated EFC decline over a period as short as 1.3 years on average, extending findings from a recent longitudinal study that discovered associations between baseline mFW and cognitive decline in cognitively normal, MCI, and Alzheimer’s disease (AD) individuals followed annually for years. These findings support the utility of the FW kit measure as a reliable and reproducible biomarker sensitive to cognition.

4.2 | Benefits of mFW in a clinical trial context

There is critical need for simple imaging biomarkers capable of measuring SVD severity for selecting individuals with cognitive complaints or early cognitive impairment potentially attributable to SVD for trials of targeted therapeutics. Using measures of late-stage pathophysiological manifestations of vascular injury, including WMH, previous clinical trials that aimed to evaluate drug treatment benefits on SVD-related injury have had mixed results. The lack of current biomarkers to capture subtle and early cerebral changes in association with SVD and the heterogeneity in available methodologies to quantify these biomarkers limit the ability of clinical trials to efficiently stratify patients. Our work suggests that mFW is sensitive to cognition even as early as the fifth decade (Gen3 cohort, see Table 3), extending findings from a previous study showing that effect of WMH on concomitant cognitive performances were fully mediated by mFW and supporting instrumental and clinical validation phases, which, to date, has been only partially addressed in the literature. Expanding upon the FW kit’s recently published instrumental validation, the most novel finding of this work is that mFW content is cross-sectionally negatively associated with a composite measure of executive function (EFC) in three MarkVCID cohorts, and, importantly, across independent subject groups from multiple legacy cohorts, offering robust support for the biomarker’s biological validity for detecting clinically meaningful changes in WM microstructure. We discuss the results of this formal process and describe the potential benefits for the use of mFW in a clinical trial context.

| TABLE 4  Effect of baseline mFW and WMH burden on baseline and change in EFC scores |
|-----------------|--------|-----------|-----------------|--------|-----------|-----------------|--------|-----------|
|                  | mFW    |           | WMH burden     |           |
|                  | Beta   | SE        | p-value         | Beta   | SE        | p-value         |
| Model M1 + VRF + WMH |        |           |                 |        |           |                 |
| Cohort 1         | −7.38  | 1.46      | <0.001          | 0.007  | 0.076     | 0.93            |
| Cohort 2         | −10.737| 2.234     | <0.001          | 0.176  | 0.094     | 0.062           |
| Cohort 3         | −3.75  | 2.091     | 0.075           | 0.029  | 0.083     | 0.73            |
| Model M2 + VRF + WMH |        |           |                 |        |           |                 |
| Longitudinal MarkVCID cohort | −2.80  | 1.07      | 0.0096          | 0.49   | 0.41      | 0.23            |

Note: Model M1 and M2 included baseline executive function composite score (EFC) and annual change in EFC as the dependent variable, respectively, and mFW as the independent variable, adjusting for age, sex, and education.

Abbreviations: mFW, mean free water; VRF, vascular risk factors including presence of diabetes, smoking, and hypertension; WMH burden corresponds to log-transformed WMH volume normalized by total cranial volume and scaled; WMH, white matter hyperintensity.
FIGURE 2  Cross-sectional association between mean Free Water (mFW) and executive function composite (EFC) scores (residualized against age, sex, and education, \([EFC_{res}]\)) in MarkVCID sub-cohorts. Johns Hopkins University School of Medicine; UCSF, Universities of California San Francisco, Davis, and Los Angeles; UKY, University of Kentucky; UNM, University of New Mexico Health Sciences Center; USC, University of Southern California; UTHSCSA, University of Texas Health Science Center at San Antonio

mFW as an early and sensitive biomarker of cognitive abilities. Correcting for VRF reduced the association between mFW and EFC scores in the MarkVCID Cohort 3 but not in Cohort 1 and Cohort 2 or in the legacy cohorts. It is notable that among all the cohorts, MarkVCID Cohort 3, despite the absence of evident recruitment strategy disparity, was also found to have the lowest average mFW content and WMH burden (see Tables S3 and S4), suggesting that SVD may be under-represented in this cohort. This finding emphasizes the importance of individual stratification during the recruitment stage of clinical trials that aim to assess cognitive decline in association with cerebrovascular disease and the promising role of mFW in this attempt. Indeed, our finding suggests that mFW may be used as a prognostic biomarker to select individuals with certain levels of cognitive decline and SVD and at high risk of experiencing accelerated cognitive decline and aggravated SVD overtime, thereby enhancing trial efficiency.

4.3  Strengths and limitations

A strength of the FW kit is that it demonstrates remarkable analytical performance. First, mFW requires DWI data, which is a non-invasive technology widely available. Therefore, as a new biomarker, it can be quickly operationalized into practice for drug development trials. Second, the FW kit includes protocol, script, and instructions that are publicly available online (https://markvcid.partners.org/consortium-protocols-resources). Third, mFW is extremely robust and precise in terms of inter-rater reliability, test-retest repeatability, and inter-scanner reproducibility. Third, DWI sequence parameters for major MRI scanner manufacturers, including Philips, Siemens Trio, Siemens Prisma, and GE, and optimized for mFW kit’s performances are publicly available, enabling multi-site MRI data research and joint and integrated data analyses. As a limitation, our statistical models considered a set of covariates, including age, sex, education, hypertension, diabetes, and smoking status. Other demographic variables, not included in this study, may have an impact on the association between FW and cognition, and further studies are needed to investigate whether other demographic variables may impact the association between FW and cognition. In the present study we focused on a composite measure of executive function. mFW is also reported to be associated with the trajectory of episodic memory and functional performances, including clinical dementia rating. However, further studies are needed to assess the sensitivity of mFW as a potential imaging biomarker of other cognitive domains or more global measures of cognition, including the Montreal Clinical Assessment (MoCA).

In summary, the present study gives clinical validation of the FW kit, an imaging-based biomarker of SVD selected by the MarkVCID consortium. Combined results from the MarkVCID cohort, and from five independent data sources, give further evidence that mean FW is a sensitive biomarker of WM injury and is significantly associated with executive function, making it a suitable candidate for future multi-site observational studies and clinical trials in the context of VCID.
**FIGURE 3** Cross-sectional association between mFW and EFC scores (residualized against age, sex, and education, [EFCres]) in legacy cohorts. RUSH used log10-transformed FW measures to normalize distribution.

**ACKNOWLEDGMENTS**

The authors thank: Bruce Fischl, Department of Radiology, Massachusetts General Hospital; Arnold M. Evia, Rush Alzheimer’s Disease Center, Rush University Medical Center; Nazanin Makkinejad, Department of Biomedical Engineering, Illinois Institute of Technology; Xin Li and Yang Li, Department of Radiology, Johns Hopkins University School of Medicine; Samantha Ma, Departments of Neurology and Radiology, Keck School of Medicine, University of Southern California; Elyas Fadaee, Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, University of Texas Health San Antonio; Andrew Warren, Mitchell Horn, and Vanessa Gonzalez, Department of Neurology, Massachusetts General Hospital; and Linda McGavern from National Institute of Health (NIH) and National Institute of Neurological Disorders and Stroke (NINDS). The Atherosclerosis Risk in Communities (AS) Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute (NHLBI) contracts (HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700004I).
Neurocognitive data are collected by U01 2U01HL096812, 2U01HL096814, 2U01HL096899, 2U01HL096902, 2U01HL096917 from the NIH (NHLBI, NINDS, National Institute of Aging (NIA), and National Institute on Deafness and Communication Disorders (NIDCD)), and with previous brain MRI examinations funded by R01-HL70825 from the NHLBI. The authors thank the staff and participants of the ARIC study for their important contributions. U24NS100591; UH3NS100599; UH3NS100588; UH3NS100608; UH3NS100605; UH3NS100606; UH3NS100598; UH3NS100614; P30 AG 010129; 5UH2NS100614-02; K23AGO61253; P30 GM 122734. The PRISMA 3T upgrade at The Mind Research Network was supported by the NIH award S10OD025313. Dr. Konstantinos Arfanakis: R01AG064233 (support to institution); R01AG052200 (support to institution); Dr. Danny Wang: R01EB028297 (support to institution); R01NS114382 (support to institution); Dr. Joel Kramer: NIH funding (support to institution); Dr. Adam Staffaroni: NIH (support to institution), Bluefield Project to Cure Frontotemporal Dementia (support to institution); Dr. Karl Helmer: NIH (support to institution), Boston Scientific (support to institution), Minoryx (support to institution); Dr. Steven Greenberg: NIH (support to Dr. Greenberg); Dr. Charles DeCarli: NIH funding (support to institution); Dr. Claudia Satizabal: Texas Alzheimer’s Research and Care Consortium/State of Texas 2020-58-81-CR (support to Dr. Satizabal and to institution).

CONFLICTS OF INTEREST
Dr. Pauline Maillard has no conflict of interest to report. Laura J. Hillmer has no conflict of interest to report. Dr. Hanzhang Lu has no conflict of interest to report. Dr. Konstantinos Arfanakis is on the advisory board for External Advisory Committee, NIH-funded clinical research study titled “Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY Network (DISCOVERY).” Dr. Brian T. Gold has no conflict of interest to report. Dr. Christopher E. Bauer has no conflict of interest to report. Dr. Lara Stables has no conflict of interest to report. Dr. Danny JJ Wang has no conflict of interest to report. Dr. Sudha Seshadri is a consultant for Biogen. Dr. Claudia L. Satizabal has received support for attending meetings and/or travel from the NIH (payment to Dr. Satizabal). Dr. Alexa Beiser has no conflict of interest to report. Dr. Myriam Fornage has no conflict of interest to report. Dr. Thomas H. Mosley has no conflict of interest to report. Dr. Gary A. Rosenberg has no conflict of interest to report. Dr. Mohammad Habes is a consultant for Biogen on ARIA. Baljeet Singh has no conflict of interest to report. Dr. Joel H. Kramer has received royalties from Pearson, Inc. Dr. Adam M. Staffaroni is a consultant to Passage Bio and Takeda. Herpreet Singh has no conflict of interest to report. Kristin Schwab has no conflict of interest to report. Dr. Karl G. Helmer has no conflict of interest to report. Dr. Steven M. Greenberg is a consultant for Roche (payment to Dr. Greenberg) and Washington University/IQVIA (payment to Dr. Greenberg), Bayer (payment to Dr. Greenberg), and Biogen (payment to Dr. Greenberg), and receives royalties or licenses from Up-To-Date (payment to Dr. Greenberg). Dr. Charles DeCarli is a consultant to Novartis on a safety trial for heart failure. Dr. Arvind Caprihan has no conflict of interest to report. Author disclosures are available in the supporting information.

REFERENCES
1. Lu H, Kashani A, Arfanakis K, et al. MarkVCID cerebral small vessel consortium: II. Neuroimaging protocols. Alzheimers Dement. 2021; 17(4):71-6725.
2. Ji F, Pasternak O, Liu S, et al. Distinct white matter microstructural abnormalities and extracellular water increases relate to cognitive impairment in Alzheimer’s disease with and without cerebrovascular disease. Alzheimers Res Ther. 2017;9:63.
3. Duering M, Finsterwalder S, Baykara E, et al. Free water determines diffusion alterations and clinical status in cerebral small vessel disease. Alzheimers Dement. 2018;14:764-774.
4. Altendahl M, Maillard P, Harvey D, et al. An IL-18-centered inflammatory network as a biomarker for cerebral white matter injury. PLoS One. 2020;15:e0227835. https://doi.org/10.1371/journal.pone.eCollection_2020
5. Maillard P, Mitchell GF, Himali JJ, et al. Aortic stiffness, increased white matter free water, and altered microstructural integrity: a continuum of injury. Stroke. 2017;48:1567-1573.
6. Mayer C, Nagele FL, Petersen M, et al. Free-water diffusion MRI detects structural alterations surrounding white matter hyperintensities in the early stage of cerebral small vessel disease. J Cereb Blood Flow Metab. 2022;42(9):1707-1718.
7. BEST (Biomarkers, Endpoints, and other Tools) Resource. Silver Spring (MD): https://www.ncbi.nlm.nih.gov/books/NBK326791/; 2016.
8. Maillard P, Lu H, Arfanakis K, et al. Instrumental validation of free water, peak-width of skeletonized mean diffusivity, and white matter hyperintensities: MarkVCID neuroimaging kits. Alzheimers Dement (Amst). 2022;14:e12261.
9. Makkinejad N, Evia AM, Tamhane AA, et al. ARTS: a novel in-vivo classifier of arteriolosclerosis for the older adult brain. Neuroimage Clin. 2021;31:102768.
10. Carmichael O, Mungas D, Beckett L, et al. MRI predictors of cognitive change in a diverse and carefully characterized elderly population. Neurobiol Aging. 2012;33(1):83-95.
11. Feineile M, Kannel WB, Garrison RJ, McNamara PM, Castelli WP. The framingham offspring study. Design and preliminary data. Prev Med. 1975;4:518-525.
28. Vipin A, Ng KK, Ji F, et al. Amyloid burden accelerates white matter degeneration in cognitively normal elderly individuals. *Hum Brain Mapp.* 2022;40:2065-2075.

29. Dumont M, Roy M, Jodoin PM, et al. Free water in white matter differentiates MCI and AD from control subjects. *Front Aging Neurosci.* 2019;11:270.

30. Bergamino C, Walsh RR, Stokes AM. Free-water diffusion tensor imaging improves the accuracy and sensitivity of white matter analysis in Alzheimer’s disease. *Sci Rep.* 2021;11:6990.

31. Hoy AR, Ly M, Carlsson CM, et al. Microstructural white matter alterations in preclinical Alzheimer’s disease detected using free water elimination diffusion tensor imaging. *PloS One.* 2017;12:e0173982.

32. Edde M, Theaud G, Rheault F, et al. Free water: a marker of age-related modifications of the cingulum white matter and its association with cognitive decline. *PloS One.* 2020;15:e0242696.

33. Gullett JM, O’Shea A, Lamb DG, et al. The association of white matter free water with cognition in older adults. *NeuroImage.* 2020;219:117040.

34. Li X, Li TQ, Andreasen N, Wiberg MK, Westman E, Wahlund LO. The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer’s disease. *J Intern Med.* 2014;275:418-427.

35. Maillard P, Himali J, Beiser A, et al. IC-P-087: association between cognition and cerebral white matter free water in adults from the framingham heart study: a diffusion tensor imaging voxel-based study. *Alzheimer Dement.* 2019;15:P77-P78.

36. Sepehrband F, Cabeen RP, Choupan J, et al. Perivascular space fluid contributes to diffusion tensor imaging changes in white matter. *NeuroImage.* 2019;197:243-254.

37. Jennings GL. Recent clinical trials of hypertension management. *Hyper tension.* 2013;62:3-7.

38. Dufouil C, Chalmers J, Coskun O, et al. Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. *Circulation.* 2005;112:1644-1650.

39. Group SMIftSR, Nasrallah IM, Pajewski NM, et al. Association of intensive vs standard blood pressure control with cerebral white matter lesions. *JAMA.* 2019;322:524-534.

**SUPPORTING INFORMATION**

Additional supporting information can be found online in the Supporting Information section at the end of this article.